Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Land & Improvements Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Growth Metrics

Others

Marimed (MRMD) Current Deferred Revenue (2016 - 2025)

Marimed (MRMD) has disclosed Current Deferred Revenue for 11 consecutive years, with $1.7 million as the latest value for Q3 2025.

On a quarterly basis, Current Deferred Revenue changed N/A to $1.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.7 million, a N/A change, with the full-year FY2024 number at $1.3 million, changed N/A from a year prior.
Current Deferred Revenue was $1.7 million for Q3 2025 at Marimed, up from $1.3 million in the prior quarter.
In the past five years, Current Deferred Revenue ranged from a high of $1.7 million in Q3 2025 to a low of $1.3 million in Q4 2024.